Spectral Genomics Forges License Agreement With Affymetrix
Spectral Genomics, Inc. of Houston, Texas announced today that it has entered a License Agreement that provides Spectral with a worldwide license to certain Affymetrix (NASDAQ:AFFX) patents to manufacture and sell spotted DNA arrays for use in the research market.
The license supports Spectral Genomics' Spectral Chip(TM) and Constitutional Chip(TM) as well as its Spectral Genomic Profiling(TM) service business. This license provides additional intellectual property enhancing Spectral's proprietary position in BAC clone whole genome arrays for research in cytogenetics and molecular biology.
Spectral Genomics' Chief Executive Officer, Edward M. Chait, Ph.D. said, "We are very pleased to be a licensee of Affymetrix and to acknowledge the contribution they have made to the science and development of the market for nucleic acid arrays while re-enforcing our own position as a leader in technology for the genome."
Spectral Genomics develops and manufactures BAC clone arrays with 3000- 6000 spots that cover the entire genome representing all the chromosomes at ten times higher resolution than with traditional cytogenetic techniques. These arrays are used in research in pre-natal and post-natal genetic defects and in cancer research. Spectral Genomics has headquarters in Houston, Texas and markets its products worldwide.
Other news from the department business & finance
